Genetron Holdings Limited (GTH)

$0.818

-0.00 (-0.23%)
Rating:
Recommendation:
-
Symbol GTH
Price $0.818
Beta 0.005
Volume Avg. 0.31M
Market Cap 73.343M
Shares () -
52 Week Range 0.731-14.6
1y Target Est -
DCF Unlevered GTH DCF ->
DCF Levered GTH LDCF ->
ROE -43.66% Strong Sell
ROA -41.99% Strong Sell
Operating Margin -
Debt / Equity 27.85% Neutral
P/E -
P/B 0.48 Neutral
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest GTH news


Dr. Wei-Wu He
Healthcare
Diagnostics & Research
NASDAQ Global Market

Genetron Holdings Limited, a precision oncology company, engages in the cancer molecular profiling, and harnessing technologies in molecular biology and data science for cancer treatment. The company offers diagnosis and monitoring services, and early screening services through laboratory developed tests services. It also provides in-vitro diagnostic products, including 8-gene lung cancer assay, an IVD assay product to detect lung cancer; Genetron 3D biochip reading instrument; Genetron S5, a semiconductor-based NGS system, which detects the nucleotide through detecting the change in pH; Genetron Chef System; Genetron S2000 platform, a production-scale sequencer; and Onco PanScan, a genomic profiling service for various solid tumors. In addition, it offers IDH1 and TERT gene assays for glioma; thyroid basic assay for thyroid tumor; platelet-derived growth factor receptor alpha assay for GIST cancer; and HCCscan, a qPCR-based assay to detect hepatocellular carcinoma. Further, it provides development services in the areas of genomics research and clinical development in collaboration with biopharmaceutical companies worldwide. The company has a strategic partnership with JD Health to create solutions for full-cycle cancer management. Genetron Holdings Limited was founded in 2015 and is headquartered in Beijing, the People's Republic of China.